Orchid Pharma
An Indian pharmaceutical company producing active pharmaceutical ingredients, finished-dose medicines, and anti-infective therapies for domestic and international markets.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Orchid Pharma is an Indian pharmaceutical company headquartered in Chennai. Founded by Kailasam Raghavendra Rao on 1 July 1992, the business began as an export-oriented pharmaceutical operation and developed into a vertically integrated manufacturer of active pharmaceutical ingredients (APIs) and finished formulations. Its activities have included drug research, process development, manufacturing, regulatory support, and international marketing. The company built its early reputation in oral and sterile cephalosporins. During the 1990s and early 2000s, it expanded manufacturing capacity and pursued internationally recognized quality systems, including ISO, good manufacturing practice, and good laboratory practice certifications. Orchid also sought to build an international presence through sales and market-entry initiatives in the United States, Europe, and China. Its growth program included collaborations with multinational pharmaceutical companies, including Merck, and the acquisition of the United States-based Bexel Biotechnology. Over time, Orchid broadened its therapeutic and commercial scope beyond its original anti-infective concentration. Its portfolio and research activities came to cover central nervous system and cardiovascular medicines, anti-inflammatory products, nutraceuticals, and other generic pharmaceutical categories. The company’s integrated model has been intended to connect research and discovery with API production, oral and sterile dosage-form manufacturing, and global commercialization. Orchid has also worked with a network of international pharmaceutical organizations through licensing, supply, and other strategic relationships. A significant part of Orchid’s later corporate history involved financial restructuring and changes to its business portfolio. In 2010, it sold its generic injectables business to Hospira in a transaction reported at approximately US$400 million. Financial difficulties subsequently led to a Corporate Debt Restructuring package in 2014. In 2017, Orchid was referred to the Corporate Insolvency Resolution Process under India’s Insolvency and Bankruptcy Code after being identified among major corporate defaulters by the Reserve Bank of India. A resolution plan submitted by Dhanuka Laboratories was eventually approved by creditors. After litigation concerning the relationship between the approved bid and the company’s liquidation value, the Supreme Court of India upheld the resolution plan in 2020. Dhanuka Laboratories implemented the plan in March 2020. Orchid is notable in India’s pharmaceutical industry for the discovery of enmetazobactam, a novel beta-lactamase inhibitor developed for use with antibiotics. The product has received regulatory approval in the United States, Europe, and India, making Orchid an unusual example of an Indian pharmaceutical company originating a new chemical entity rather than focusing exclusively on manufacturing established generic medicines. The company’s current identity combines its historical strengths in anti-infective APIs and formulations with a continuing emphasis on generics, research-derived products, and international pharmaceutical supply.
History
Orchid Pharma was established in Chennai on 1 July 1992 by Kailasam Raghavendra Rao. It began as an export-oriented pharmaceutical company and gradually developed manufacturing, research, and international marketing capabilities. During its first phase of expansion, Orchid concentrated on active pharmaceutical ingredients and finished formulations, especially oral and sterile cephalosporins. The company’s manufacturing operations pursued international quality certifications and were positioned to supply regulated and emerging markets. In the 1990s and early 2000s, Orchid expanded its geographic ambitions beyond India. It targeted the United States, European countries, and China and developed relationships with overseas pharmaceutical organizations. Its strategic activities included research collaborations with companies such as Merck and the acquisition of Bexel Biotechnology in the United States. The company also diversified into chronic therapies and drug discovery. Its manufacturing and research profile attracted public attention in India, including a visit to its facilities by former President A. P. J. Abdul Kalam. Orchid’s business model became increasingly integrated. In addition to producing APIs, the company manufactured oral and sterile dosage forms and maintained activities in research, product development, regulatory work, and marketing. Its therapeutic interests extended across anti-infectives, central nervous system products, cardiovascular medicines, anti-inflammatory treatments, and nutraceuticals. The company also pursued alliances with a broad group of international pharmaceutical organizations, with global generics and API supply remaining important strategic areas. The company’s portfolio changed substantially in 2010 when it sold its generic injectables business to Hospira for a reported US$400 million. Although the transaction represented a major strategic and financial event, Orchid later faced financial stress. A Corporate Debt Restructuring package was introduced in 2014. In August 2017, the Reserve Bank of India identified Orchid among 28 large corporate defaulters, and the company was referred to the Corporate Insolvency Resolution Process under the Insolvency and Bankruptcy Code. An initial insolvency bid from Ingen Capital did not succeed. In a subsequent bidding process, the Committee of Creditors approved a resolution plan from Dhanuka Laboratories valued at ₹1,116 crore. The National Company Law Appellate Tribunal initially rejected the plan because the offer was below the stated liquidation value of ₹1,309 crore. The Supreme Court of India later overturned that decision in 2020, holding that the insolvency framework did not require an approved resolution offer to match or exceed liquidation value and that creditor commercial judgment was central to the process. Dhanuka Laboratories implemented the plan in March 2020, becoming Orchid Pharma’s controlling owner. Orchid’s research history is particularly associated with enmetazobactam, a beta-lactamase inhibitor intended to be used with antibiotics. The compound’s approvals in the United States, Europe, and India gave Orchid a distinctive position among Indian pharmaceutical companies. Unlike a business focused solely on contract production or established generics, Orchid has combined API manufacturing and finished formulations with new-drug discovery. Its contemporary profile therefore reflects both its historical manufacturing base and its effort to develop differentiated anti-infective products for international markets.
- 2020
Supreme Court validates the resolution plan
[1]The Supreme Court of India upholds Dhanuka Laboratories’ resolution plan and emphasizes creditors’ commercial judgment in the insolvency process.
- 2020
Dhanuka Laboratories implements the plan
[1]Dhanuka Laboratories completes implementation of the approved plan and assumes control of Orchid Pharma.
- 2017
Referral to insolvency resolution
[1]The company is referred to the Corporate Insolvency Resolution Process under India’s Insolvency and Bankruptcy Code.
- 2014
Corporate Debt Restructuring package
[1]Orchid enters a Corporate Debt Restructuring arrangement amid financial difficulties.
- 2010
Generic injectables business sold to Hospira
[1]Orchid transfers its generic injectables business to Hospira in a transaction reported at approximately US$400 million.
- 2000
Expansion into international pharmaceutical markets
[1]During the 1990s and early 2000s, Orchid expands its manufacturing and commercial activities toward the United States, Europe, and China while strengthening its cephalosporin business.
- 2000
Research and biotechnology expansion
[1]The company develops research collaborations, including work associated with Merck, and acquires the United States-based Bexel Biotechnology.
- 1992
Orchid Pharma is founded
[1]Kailasam Raghavendra Rao establishes Orchid as an export-oriented pharmaceutical company in Chennai on 1 July.
Products and positioning
A vertically integrated Indian pharmaceutical manufacturer with historical strength in cephalosporin APIs and formulations, an international generics orientation, and a distinctive research profile associated with enmetazobactam.
Novel anti-infective pharmaceutical
Enmetazobactam
Enmetazobactam is a beta-lactamase inhibitor discovered by Orchid Pharma for use in combination with antibiotics. Its regulatory approvals in the United States, Europe, and India represent a major research achievement for the company and distinguish Orchid from Indian manufacturers focused only on established generic compounds. The product is associated with the company’s drug-discovery and anti-infective strategy.
Anti-infective pharmaceuticals
Cephalosporin APIs and formulations
Orchid developed a substantial historical business in oral and sterile cephalosporins. Its activities have covered both the manufacture of active pharmaceutical ingredients and finished dosage forms, allowing the company to participate across multiple stages of the pharmaceutical value chain. Cephalosporins remain central to Orchid’s historical identity as an Indian anti-infective manufacturer.
Finished-dose pharmaceuticals
Generic oral formulations
Orchid’s oral formulation activities include finished generic medicines supplied for domestic and international markets. The company’s broader portfolio has covered anti-infective, central nervous system, cardiovascular, anti-inflammatory, and other therapeutic categories. These products complement its API manufacturing and support its vertically integrated generics model.
Finished-dose pharmaceuticals
Sterile formulations
Sterile formulations formed part of Orchid’s manufacturing capabilities and were particularly important to its anti-infective and injectables activities. The company later sold its generic injectables business to Hospira in 2010, so the status of individual sterile products and facilities may differ from Orchid’s earlier portfolio.
Brand decisions
2020
Dhanuka Laboratories takes control through insolvency resolutionM&ABackground
The National Company Law Appellate Tribunal had initially rejected Dhanuka Laboratories’ bid because it was below the stated liquidation value of ₹1,309 crore.
Action taken
The Supreme Court overturned that rejection, affirmed the creditors’ commercial judgment, and allowed the resolution plan to proceed.
Aftermath
Dhanuka Laboratories implemented the plan in March 2020 and became Orchid Pharma’s owner and controlling group.
Stated liquidation value. ₹1,309 crore (2017-2020 insolvency proceedings)
2017
Entry into the Corporate Insolvency Resolution ProcessOtherBackground
The Reserve Bank of India identified Orchid among 28 large corporate defaulters under the framework that led to insolvency referrals.
Action taken
Orchid was referred for resolution under India’s Insolvency and Bankruptcy Code. After an initial unsuccessful bid, creditors approved a plan submitted by Dhanuka Laboratories.
Aftermath
The resolution process resulted in Dhanuka Laboratories becoming the company’s controlling owner after the Supreme Court upheld the plan in 2020.
Approved resolution plan value. ₹1,116 crore (2017)
2014
Corporate Debt RestructuringStrategyBackground
Orchid faced financial difficulties after a period of expansion and portfolio changes.
Action taken
The company entered a Corporate Debt Restructuring package.
Aftermath
The restructuring did not resolve all financial pressures, and Orchid was later referred to the Corporate Insolvency Resolution Process.
2010
Divestment of generic injectables businessM&ABackground
Orchid was reshaping its pharmaceutical portfolio and pursued a major transaction involving its generic injectables business.
Action taken
The company sold the generic injectables business to Hospira in a transaction reported at approximately US$400 million.
Aftermath
The divestment represented a major change in Orchid’s business scope and was followed in later years by financial restructuring and insolvency proceedings.
Reported transaction value. Approximately US$400 million (2010)
Recent events
- 2020
Supreme Court upholds Dhanuka Laboratories’ resolution plan[1]
Bankruptcy · Regulation · M&A
The Supreme Court of India upheld creditors’ approval of Dhanuka Laboratories’ plan for Orchid Pharma and ruled that an insolvency resolution offer did not have to equal or exceed the liquidation value.
- 2020
Dhanuka Laboratories implements Orchid Pharma resolution plan[1]
Bankruptcy · M&A
Dhanuka Laboratories completed implementation of the resolution plan approved through the insolvency process, marking a change in Orchid Pharma’s ownership and corporate control.
- 2017
Orchid Pharma enters corporate insolvency resolution[1]
Bankruptcy · Regulation
Orchid Pharma was referred to India’s Corporate Insolvency Resolution Process under the Insolvency and Bankruptcy Code after being identified among major corporate defaulters.
- 2010
Orchid Pharma sells generic injectables business to Hospira[1]
M&A
Orchid transferred its generic injectables business to Hospira in a transaction reported at approximately US$400 million, reshaping the company’s portfolio and capital position.
Enmetazobactam receives approvals in the United States, Europe, and India[1]
Product launch · Regulation
Orchid Pharma’s discovered new chemical entity enmetazobactam received regulatory approval in the United States, Europe, and India, supporting the company’s research-led anti-infective positioning.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/orchid-pharma · Editorial policy · How profiles are compiled